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ABSTRACT
Purpose: Oncology nurses in ambulatory settings are at
increased risk for unintentional chemotherapy
exposure due to the large volumes of agents delivered
and the absence of regulatory enforcement. Given the
limited data regarding the correlates of exposure, the
authors sought to identify the relationship between the
organisational structures and processes of care in
ambulatory oncology settings associated with
increased risk of unintentional chemotherapy.
Methods: Between April 2010 and June 2010, a state-
wide sample of oncology nurses were surveyed who
reported their employment outside of hospital inpatient
units (n¼1339). The survey examined the likelihood of
self-reported exposure to chemotherapy as a function
of perceived quality of the practice environment,
nursing workload, and seven ambulatory
chemotherapy administration safety standards.
Results: The response rate was 30.4%, with minimal
demographic differences observed between respondents
and non-respondents. The overall rate of exposure to the
skin or eyes in the past year was 16.9%. In multivariable
logistic regression models that controlled for
demographic characteristics and clustering of nurses in
practices, the likelihood of exposure decreased when
nurses reported adequate staffing and resources (OR
0.35, 95% CI 0.17 to 0.73; p¼0.001), and when nurses
reported that chemotherapy doses were verified by two
nurses frequently or very frequently (OR 0.17, 95%
CI 0.05 to 0.59; p¼0.001).
Conclusions: Oncology nurses in the ambulatory
setting report substantial unintentional skin and eye
exposure to chemotherapy. Ensuring adequate staffing
and resources and adherence to recognised practice
standards may protect oncology nurses from harm.
INTRODUCTION
Chemotherapy administration is a high-
priority target for quality improvement activ-
ities given high patient volumes and high
risks to patients and clinicians. In the United
States, an estimated 23 million adult patient
visits occur annually for chemotherapy. Of
these visits, approximately 19 million (84%)
are delivered in ambulatory settings, largely
by nurses.1 And despite numerous concerns
for chemotherapy safety, less attention is paid
to the risks that nurses face when they
administer these agents and are uninten-
tionally exposed because of a splash or spill.
The antineoplastic drugs used for chemo-
therapy (eg, cyclophosphamide, ifospha-
mide, paclitaxel, methotrexate) confer
significant health risks, such as immediate
nervous system effects, acute and long-term
reproductive effects, and subsequent risk of
haematological malignancies.2 3
The absence of a consistent regulatory
framework for chemotherapy delivery in
ambulatory oncology settings exacerbates the
potential risk to nurses. Apart from a recent
Centres for Medicare and Medicaid Services
statement4 that a ‘physician or non-physician
practitioner’s recurrent physical presence’ is
required during chemotherapy administra-
tion, Centres for Medicare and Medicaid
Services performs little oversight of chemo-
therapy delivery. The National Institute for
Occupational Safety and Health issued an
alert on occupational exposure to antineo-
plastic and other hazardous drugs.5 However,
this alert is merely advisory and has no
regulatory enforcement.
Chemotherapy administration processes
vary across practices. In 2009, the Oncology
Nursing Society (ONS) and American Society
of Clinical Oncology (ASCO) acknowledged
the potential problems imposed by practice
variability and jointly issued voluntary safety
standards for ambulatory chemotherapy
< An additional appendix is
published online only. To







Michigan School of Nursing,
Ann Arbor, Michigan, USA
2University of Michigan









Michigan School of Nursing,






Ann Arbor, Michigan, USA
Correspondence to
Dr Christopher R Friese,
Nursing Business and Health
Systems, University of
Michigan School of Nursing,
400 N. Ingalls 4162, Ann
Arbor, MI 48109-5482, USA;
cfriese@umich.edu
Accepted 6 July 2011
Original research
BMJ Qual Saf 2012;21:753–759. doi:10.1136/bmjqs-2011-000178 753
Published Online First
16 August 2011
administration.6 The adoption rate of these standards is
unknown, and only 74 practices are certified currently by
ASCO’s Quality Oncology Practice Initiative for standard
adherence.7 The 17 standards assessed for Quality
Oncology Practice Initiative certification do not address
safe handling practices and related policies. Further, no
reporting mechanism exists to track unintentional
exposures to chemotherapy or the conditions under
which the exposure occurred.
Noteworthy challenges to existing efforts to study
unintentional exposure include measurement consider-
ations and restricted sampling. Diverse measurement
approaches and result interpretation vary across studies
and hamper comparability. Studies conducted in the
1980s and 1990s examined both urine mutagenicity and
drug levels excreted in urine.8e10 More recently, bio-
logical measures have been correlated to healthcare
workers’ self reports.11 Self report has been used
successfully in assessing needle stick injuries to nurses.12
A second limitation of the literature is the absence of
multi-site, population-based samples. Because of its cost,
biological sampling has been limited to convenience
samples of single institutions, which limits general-
isability to more diverse practices and participants.13 14
Taken together, these limitations hamper examinations
of variation in chemotherapy exposure across settings,
and the correlates of increased exposure.
Published studies have not examined the relationship
between chemotherapy exposure and the structures
and processes employed by oncology practices. The
decentralised nature of ambulatory chemotherapy
administration hampers research efforts to study this
problem. A better understanding of the organisational
structures and processes of care that are associated with
chemotherapy exposure to nurses in ambulatory
oncology settings would inform policymakers, safety
officials, managers, and clinicians on how best to reduce
exposure risk and minimise harm to oncology nurses. In
this context, we conducted a state-wide survey of
oncology nurses employed outside of hospital inpatient
units to quantify reported exposure and to identify
organisational correlates of exposure.
METHODS
Study design and setting
Donabedian’s Quality of Care Model15 guided our study
design. This model identified three components of
quality: the organisational structures (eg, staffing, work-
place context, leadership, management), the processes
of care (eg, clinical and technical interventions
provided), and the outcomes (eg, safety, satisfaction, and
clinical endpoints). This report focuses on the organ-
isational structures and processes of care in ambulatory
oncology settings, and their relationship to the safety
outcome of nurse-reported chemotherapy exposure.
Completed between April and June, 2010, the Practice
Environments of Oncology Nurses Study was a cross-
sectional survey that examined nurse reports of the
organisational structures, processes of care, and
outcomes in ambulatory oncology settings; we have
published our methodology previously.16 Briefly, we used
nursing registry data from one state in the southeast
USAdupdated bienniallydto identify registered and
licensed practical nurses who resided in the state and
who reported a clinical specialty of oncology and
a practice setting outside of hospital inpatient units
(n¼1339). We modified the Dillman survey method17 by
including a $2 up-front incentive, a shorter interval for
reminder notices, and randomised nurses to Internet
versus paper survey completion. We observed no signif-
icant differences in response rates across arms.16
We obtained human subjects approval from the Univer-
sity of Michigan’s Institutional Review BoarddMedicine.
Measures
The internet and paper questionnaires had identical
content. In addition to sociodemographic variables, the
questionnaires included measures of organisational
structure, processes of care, and perceived outcomes.
Organisational structure
Nurses completed the Practice Environment Scale of the
Nursing Work Index (PES-NWI).18 The PES-NWI
consists of 31 items that assess the presence of organ-
isational features to support professional nursing prac-
tice and promote favourable patient outcomes. The
original PES-NWI includes five subscales: nurse partici-
pation in hospital affairs; nursing foundations for quality
of care; nurse manager leadership, ability, and support
of nurses; staffing and resource adequacy; and collegial
nurseephysician relationships. The instrument has
published evidence of reliability (Cronbach a values
between 0.71 and 0.84 across subscales) and validity
(higher PES-NWI scores for nurses employed in Magnet
hospitals),19 20 albeit in samples of inpatient nurses.
Using focus groups,21 clinical nursing expert review,
and cognitive interviews, we modified the items slightly
for suitability to the outpatient environment. The revised
PES-NWI had six subscales: the original five listed above
plus the supportive relations with medical assistants
subscale. The revised text of the revised items and
corresponding subscales is available in the online
appendix. In a previous study, we performed confirma-
tory factor analysis using structural equation modelling
to examine model fit with revised items. In our final
model specifying six constructs, a reduced set of 23
items achieved acceptable model fit, as reflected by
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a comparative fit index of 0.95 and a root mean-square
error of approximation of 0.057 (95% CI 0.049 to
0.064).22 Cronbach a coefficients for the subscales
ranged from 0.80 to 0.90. Items were scored on a five-
point Likert scale, ranging from 1¼strongly disagree the
characteristic was present in the workplace to 5¼strongly
agree the characteristic was present in the workplace.
Subscale items were averaged for each nurse, where
values above 3.0 suggested the presence of the charac-
teristic in their workplace. Mean PES-NWI subscales were
used in bivariate analysis, and later were dichotomised
(>3.0 vs 3.0 and under) for use in multivariable models.
In addition to the revised PES-NWI subscales, we asked
each participant an additional item: ‘please describe the
current practice environment for you as a nurse to
delivery high-quality care’. Response options were
favourable, mixed, or unfavourable.
To measure nursing workload, we used each nurse’s
report of the number of patients for whom they assumed
the primary care on their last shift, and treated this
measure as a continuous variable. This measure of nursing
workload has been used in prior studies of hospital
staffing and patient outcomes, and correlates well with
both perceived staffing adequacy and administratively
derived nurse staffing.19 23
Processes of care
We developed seven process of care items from the 2009
ASCO/ONS standards for ambulatory chemotherapy
administration.6 Nurses rated the frequency that the
process occurred on a five-point Likert scale (never to
very frequently). Items included the presence of signed
informed consent, documentation of treatment intent,
and performance of pain assessments. In our explor-
atory data analysis, we identified only one process of care
measuredthe frequency that two nurses performed
verification of the original chemotherapy order against
the prepared dosage of chemotherapydthat was associ-
ated with the likelihood of chemotherapy exposure. We
treated this dichotomously (verified chemotherapy
order and dosage very frequently or frequently versus
occasionally, rarely, very rarely, or never).
Outcome
The primary outcome was nurse-reported exposure of
a chemotherapeutic agent to their skin or to their eyes in
the past year. We restricted our analyses to comparing
nurses who reported zero versus one or more exposures
in the past year (n¼242).
Nursing characteristics
We included the following nurse-reported covariates in
our models: race (white or non-white), certification in
oncology nursing (certified or not certified), and
education level (bachelor’s degree or higher or less than
a bachelor’s degree).
Analysis
First, we examined the response rate and non-response
bias by comparing the demographic characteristics of
our analytic sample from individuals who either did not
respond at all to the survey, or did not answer the
question regarding chemotherapy exposure. These
demographic variables were provided on the entire
sampling frame from the registry. Next, exposure to
chemotherapy was treated as a binary variable (exposed
vs not exposed), and bivariate analyses of the associa-
tions between categorical measures (perception of nurse
practice environment, oncology certification and
education level) were compared by exposure status using
chi-square tests of independence. Differences in PES-
NWI subscales (treated as continuous measures) and
nursing workloads were conducted using two-sample
t tests of mean differences.
Logistic regression, adjusted for clustering of nurses
within practices (SAS GENMOD), was used to model
odds of exposure among respondents. Six models
were estimated. First, we estimated models to examine
likelihood of chemotherapy exposure associated with
perceived practice environment (model I), nursing
workload (model II), and chemotherapy verification
(model III). Two models were estimated for perceived
practice environment (model IV) and chemotherapy
verification (model V) that were adjusted for the
following: nurse characteristics (race, education, experi-
ence as a nurse, and oncology certification status); and
nursing workload. Model VI examined perceived practice
environments and was adjusted for nurse characteristics,
nurse workload, and chemotherapy verification. For our
final model (VII), we used a backward selection process
(p>0.20) to retain the PES-NWI subscales related to
chemotherapy exposure.24 This model was adjusted for
nursing workload, chemotherapy verification, and nurse
characteristics. The overall perception of practice envi-
ronment measure was excluded from this final analysis
because the PES-NWI measures are considered compo-
nents of the overall measure. All tests were two tailed and
significance was established at a Cronbach a of 0.05. All
analyses were performed using SAS V.9.2 .
Sensitivity analyses
We performed two sets of sensitivity analyses. Because of
the relatively high rates of outcome and exposure, we
replicated our analytic approach by specifying a Poisson
distribution and calculating prevalence ratios that were
adjusted for clustering.25 Second, because missing data
on PES-NWI items would exclude the respondent from
the logistic regression models, we replicated our models
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using the multiple imputation function in SAS V.9.2.26
Specifically, we used a maximum likelihood function to
replicate five complete datasets, and re-analyse the
results from our final logistic regression model.
RESULTS
Response rate and analytic sample
Of the 402 nurses who responded to the survey (response
rate of 30.5%),27 this analysis was restricted to nurses who
responded to the chemotherapy exposure item: ‘In the
past year, please indicate the number of times you have
been exposed to a chemotherapeutic agent to your skin
or eyes’ (n¼242). First, we examined demographic
differences between our analytic sample and nurses who
did not respond to the survey (n¼937), or respond to the
chemotherapy exposure question (n¼160) using data
provided by the registry on the entire sampling frame
(table 1). Except for a higher proportion of nurses who
did not respond employed outside of hospital ambula-
tory or physician practices, we observed no significant
differences in observed demographics between our
analytic sample and those who did not respond.
Next, we examined more detailed characteristics of
our analytic sample (n¼242). The individual character-
istics of nurses who were exposed (race, oncology certi-
fication status, and education level) did not differ
significantly from those who were not exposed (table 2).
Though not significant, 23 or 62.2% of nurses who were
exposed reported a favourable practice environment
versus 142 or 74.7% of nurses who were not exposed to
chemotherapy (p¼0.12).
Compared with nurses who did not report exposure
to chemotherapy within the last year, those who were
exposed had lower (worse) scores on several PES-NWI
subscales. Mean scores on the participation in practice
affairs and staffing and resource adequacy subscales
differed by exposure status: 3.16 for nurses who were not
exposed versus 2.73 for those who were exposed on a five-
point scale (p< 0.01), and 3.61 for nurses who were not
exposed versus 3.01 for those who were exposed
(p<0.001). Compared with nurses who were exposed, the
means of the remaining subscales (nurse manager lead-
ership, ability, and support, collegial nurseephysician
relations, nursing foundations for quality of care, and
supportive medical assistant relations) were higher among
those who reported no exposure, but the differences were
not significant. Nurses who were exposed reported an
average patient assignment of 11.1 patients per shift
versus 8.43 patients per shift reported by those who were
not exposed (p¼0.02). The reported nurse workload
across the sample ranged from 0 to 38 patients on the last
shift. Chemotherapy orders were verified by two or more
nurses on a frequent or very frequent basis 94.5% of the
time for the entire sample, although only 82.9% of nurses
exposed to chemotherapy indicated this was the case for
them (compared with 96.9% of nurses not exposed to
chemotherapy, p<0.01). Years employed as a nurse did
not differ significantly by exposure status (p¼0.58).
Multivariable models (table 3) were used to examine
the relationships between chemotherapy exposure and
organisational structures, and processes of care. Models
IeIII yielded significant relationships between reported
chemotherapy exposure and practice environment,
nursing workload, and chemotherapy verification,
respectively, and were adjusted for nurse characteristics.
In model IV, after adjusting for nurse characteristics and
nursing workload, nurses who reported favourable
Table 1 Demographic characteristics of the analytic sample and of nurses who did not respond
Analytic sample
(n[242)
Nurses in sampling frame who
did not respond (n[1097)
n (%) p
Employed full time 146 (85.4) 913 (88.6) 0.25
Employed part time 25 (14.6) 118 (11.4)
White 157 (91.8) 973 (94.4) 0.22
Non-white 14 (8.2) 58 (5.6)
Women 166 (97.1) 994 (96.4) 0.65
Men 5 (2.9) 37 (3.6)
Hospital outpatient 97 (56.7) 575 (55.8) 0.01
Physician practice 65 (38.0) 320 (31.0)
Other practice setting 9 (5.3) 136 (13.2)
Less than Bachelor’s degree 86 (50.3) 521 (50.5) 1.0
Bachelor’s degree or higher 85 (49.7) 510 (49.5)
Resides in an MSA 129 (75.4) 819 (79.4) 0.26
Resides outside of an MSA 42 (24.6) 212 (20.6)
Nurses in the sampling frame who did not respond include 160 who did not answer the chemotherapy exposure question, and 937 who did not
return the questionnaire. Demographic characteristics from the state’s nursing registry were not available for 254 nurses in the sampling frame.
MSA, metropolitan statistical area.
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practice environments (as opposed to unfavourable or
mixed environments) had a significantly lower likeli-
hood for exposure (OR 0.44, 95% CI 0.21 to 0.92). In
model V, after adjustment for nurse characteristics and
nursing workloads, frequent or very frequent use of
chemotherapy verification was associated with a signifi-
cant reduction in exposure likelihood (OR 0.21, 95% CI
0.07 to 0.61). Model VI reports a significantly decreased
likelihood of exposure for nurses who report favourable
environments (as opposed to unfavourable/mixed
environments), after adjusting for nurse characteristics,
nursing workloads, and chemotherapy verification (OR
0.45, 95% CI 0.21 to 0.95).
One final model (model VII, right-sided panel of
table 3) included specific PES-NWI subscales, nursing
workloads, and verification of chemotherapy. Individual
nurse characteristics were included in the model, but
not displayed. Nurses were less likely to report chemo-
therapy exposure when they reported staffing and
resources were adequate (OR 0.35, 95% CI 0.17 to 0.73).
Nurses who reported that chemotherapy orders and
doses were consistently verified by two nurses had
a significantly lower likelihood of chemotherapy
exposure (OR 0.17, 95% CI 0.05 to 0.59).
Sensitivity analysis
Our findings did not change when we specified
a Poisson distribution and calculated prevalence ratios.
Our results also did not change when the entire sample
was used in a maximum-likelihood, five-dataset multiple
imputation model to address missing data.
DISCUSSION
In this state-wide sample of ambulatory oncology nurses,
we identified a high rate of self-reported skin or eye
exposure to chemotherapy (16.9%). While there is no
target level of ‘acceptable’ exposure, unintentional
occupational exposure to antineoplastics could be
Table 2 Nurse-reported exposure to chemotherapy compared with work environment and individual level characteristics
(n¼242)
Exposed to chemotherapy




Nurse participation in practice affairs 2.73 (0.69) 3.16 (0.80) <0.01
Nurse manager leadership and ability 3.37 (0.84) 3.57 (0.92) 0.20
Collegial nurseephysician relations 3.89 (0.63) 4.01 (0.73) 0.34
Staffing and resource adequacy 3.01 (1.00) 3.61 (0.91) <0.01
Nursing foundations for quality of care 4.04 (0.54) 4.17 (0.60) 0.22
Supportive relations with medical assistants 3.41 (1.06) 3.62 (1.02) 0.25
Nursing workloads
Number of patients primarily responsible
for on last shift
11.11 (6.44) 8.43 (5.99) 0.02
n (%) py
Perception of nurse practice environment
Unfavourable or mixed 14 (37.8) 48 (25.3) 0.12
Favourable 23 (62.2) 142 (74.7)
Process
Chemotherapy orders and dosages are
verified by two nurses
Infrequently 7 (17.1) 6 (3.1) <0.01
Frequently or very frequently 34 (82.9) 188 (96.9)
Nurse characteristics
Race
Non-white 6 (14.6) 15 (7.5) 0.14
White 35 (85.4) 185 (92.5)
Oncology certification
Not certified 8 (19.5) 56 (27.9) 0.27
Certified 33 (80.5) 145 (72.1)
Education level
Less than a bachelor’s degree 25 (61) 106 (52.7) 0.33
Bachelor’s degree or higher 16 (39) 95 (47.3)
*Differences in exposure tested using two sample t tests.
yDifferences in exposure tested using the chi-square test of independence. In cases of small cell sizes, Fisher’s exact test was used.
PES-NWI, Practice Environment Scale of the Nursing Work Index.
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considered a ‘never’ event, given the risks for harm. Both
the structure and processes of ambulatory chemotherapy
settings were associated with exposure. Favourable
practice environments, lower nursing workloads, and
adherence to two-nurse chemotherapy verification were
protective. These relationships persisted after control-
ling for clustering of nurses in practices. Individual
characteristics of nurses, such as years of experience,
were not associated with exposure.
While it is not surprising that favourable practice
environments and lower workloads for nurses were
associated with reduced exposure, our finding of a rela-
tionship between chemotherapy exposure and dose
verification is intriguing. Practices that adhere to this
ASCO/ONS endorsed practice6 likely are predisposed to
a positive safety culture. Thus, the verification process
may not directly influence exposure but rather may serve
as a proxy for various processes to protect patients and
nurses. Direct measures of safety behaviours28 may clarify
the mechanisms by which practices can protect nurses
from potential harm.
Our study contributes to the literature in two impor-
tant ways. First, it is one of the few to use a sampling
frame of a diverse population of nurses employed outside
of inpatient care units. The previous studies have focused
on purposive samples from settings that have agreed to
participate.8e11 13 14 Facilities that participate in chemo-
therapy safety studies are likely to have heightened
awareness of the risks and implement processes to
protect employees. Second, we included and identified
aspects of nurses’ daily working conditions that are
associated with increased exposure risk. The contribu-
tion of organisational structures and processes to
exposure risk has not been reported previously.29
It is encouraging to note that the organisational
characteristics associated with increased chemotherapy
exposure are modifiable by leadership. Practice
managers can distribute nursing workloads more evenly,
assure the availability of adequate time, space, and
personnel for chemotherapy verification, and assure that
requisite resources are available to administer chemo-
therapy in ways that minimise occupational exposure.
Our findings also suggest that the current safety culture
in ambulatory oncology practices could be strengthened
to minimise risks to oncology nurses.
Limitations
We did not measure nurses’ use of safety devices,
protective equipment, and adoption of protocols to
minimise chemotherapy exposure. We also did not
obtain information about the activities performed at the
time of exposure (eg, mixing, administering, discon-
necting, or disposal). These factors likely influence
exposure risk and should be included in future studies.
Second, our response rate, while within the range of
recently published response rates of nursing personnel,
raises concern for non-response bias. Except for practice
setting, we observed no significant systematic differences
between nurses who responded versus those who did not
respond; this reduces concerns for bias.30 Our non-
response analysis suggests that nurses who did not
respond were less likely to practice in hospital ambula-
tory or private practices, which are the target areas for
our study. Third, our study did not include biological
measures (eg, urine, blood, or surface swipe tests) to
validate the self report of exposure. Historically,
nurses have served as reliable informants on quality and
safety phenomena.12 In some cases, nurse reports of
operational failures are lower than independent obser-
vation, which suggests that nurses may underreport
exposure.31 This would suggest that our exposure esti-
mates are conservative. Finally, we interpret the
Table 3 Odds of exposure to chemotherapy, as estimated by structure and process variables, n¼185*











Model I IV VI VII
Favourable practice
environment
0.49 (0.24 to 1.00) 0.44 (0.21 to 0.92) 0.45 (0.21 to 0.95) e
Model II
Nursing workload 1.07 (1.02 to 1.12) e e 1.06 (0.99 to 1.12)
Model III V
Chemotherapy verification 0.22 (0.08 to 0.62) 0.21 (0.07 to 0.61) e 0.17 (0.05 to 0.59)
Revised PES-NWI subscales
Nurse participation in practice affairs (favourable vs unfavourable) 0.51 (0.24 to 1.06)
Staffing and resource adequacy (favourable vs unfavourable) 0.35 (0.17 to 0.73)
*All models adjusted for clustering of nurses within practices using a generalised model function.
PES-NWI, Practice Environment Scale of the Nursing Work Index.
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relationship between nursing workload and chemo-
therapy exposure with caution, as the reported workload
of respondents ranged from 0 to 38 patients. However,
our discussions with practicing oncology nurses confirm
the wide variation in daily workloads.21
Summary and practice implications
In this state-wide sample of oncology nurses practicing
outside of hospital inpatient units, we observe high rates
of nurse-reported chemotherapy exposure to their skin
and eyes. Clinicians and managers can partner to
manage workloads and implement steps to promote safe
practices of hazardous drug administration. These
include education, appropriate safety devices, personal
protective equipment, and management support to
adopt these methods by clinicians. Robust efforts to
provide for the safety of patients receiving chemotherapy
should be extended to the providers who administer this
potentially harmful therapy.
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